{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:50:09Z","timestamp":1787730609695,"version":"build-2784847793"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dysphagia"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Autoimmune neurogenic dysphagia refers to manifestation of dysphagia due to autoimmune diseases affecting muscle, neuromuscular junction, nerves, roots, brainstem, or cortex. Dysphagia is either part of the evolving clinical symptomatology of an underlying neurological autoimmunity or occurs as a sole manifestation, acutely or insidiously. This opinion article reviews the autoimmune neurological causes of dysphagia, highlights clinical clues and laboratory testing that facilitate early diagnosis, especially when dysphagia is the presenting symptom, and outlines the most effective immunotherapeutic approaches. Dysphagia is common in inflammatory myopathies, most prominently in inclusion body myositis, and is frequent in myasthenia gravis, occurring early in bulbar-onset disease or during the course of progressive, generalized disease. Acute-onset dysphagia is often seen in Guillain\u2013Barre syndrome variants and slowly progressive dysphagia in paraneoplastic neuropathies highlighted by the presence of specific autoantibodies. The most common causes of CNS autoimmune dysphagia are demyelinating and inflammatory lesions in the brainstem, occurring in patients with multiple sclerosis and neuromyelitis optica spectrum disorders. Less common, but often overlooked, is dysphagia in stiff-person syndrome especially in conjunction with cerebellar ataxia and high anti-GAD autoantibodies, and in gastrointestinal dysmotility syndromes associated with autoantibodies against the ganglionic acetyl-choline receptor. In the setting of many neurological autoimmunities, acute-onset or progressive dysphagia is a potentially treatable condition, requiring increased awareness for prompt diagnosis and early immunotherapy initiation.<\/jats:p>","DOI":"10.1007\/s00455-021-10338-9","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T15:02:55Z","timestamp":1625497375000},"page":"473-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Autoimmune Neurogenic Dysphagia"],"prefix":"10.1007","volume":"37","author":[{"given":"Panos","family":"Stathopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-1134","authenticated-orcid":false,"given":"Marinos C.","family":"Dalakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"10338_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"key":"10338_CR2","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487\u201398.","journal-title":"N Engl J Med"},{"key":"10338_CR3","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMra1402225","volume":"372","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734\u201347.","journal-title":"N Engl J Med."},{"key":"10338_CR4","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70:360\u201374.","journal-title":"Medicine (Baltimore)"},{"key":"10338_CR5","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.3390\/jcm9072150","volume":"9","author":"B Labeit","year":"2020","unstructured":"Labeit B, Pawlitzki M, Ruck T, Muhle P, Claus I, Suntrup-Krueger S, et al. The impact of dysphagia in myositis: a systematic review and meta-analysis. JCM. 2020;9:2150.","journal-title":"JCM"},{"key":"10338_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","volume":"74","author":"C Dobloug","year":"2015","unstructured":"Dobloug C, Garen T, Bitter H, Stj\u00e4rne J, Stenseth G, Gr\u00f8vle L, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis. 2015;74:1551\u20136.","journal-title":"Ann Rheum Dis"},{"key":"10338_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/01.rhu.0000164820.46979.52","volume":"11","author":"G R\u00edos","year":"2005","unstructured":"R\u00edos G. Retrospective review of the clinical manifestations and outcomes in puerto ricans with idiopathic inflammatory myopathies. JCR J Clin Rheumatol. 2005;11:153\u20136.","journal-title":"JCR J Clin Rheumatol"},{"key":"10338_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","volume":"20","author":"PW Wolstencroft","year":"2018","unstructured":"Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20:28.","journal-title":"Curr Rheumatol Rep"},{"key":"10338_CR9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/rheumatology\/ken029","volume":"47","author":"NJ Sheehan","year":"2008","unstructured":"Sheehan NJ. Dysphagia and other manifestations of oesophageal involvement in the musculoskeletal diseases. Rheumatology. 2008;47:746\u201352.","journal-title":"Rheumatology"},{"key":"10338_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","volume":"77","author":"JB Lilleker","year":"2018","unstructured":"Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77:30\u20139.","journal-title":"Ann Rheum Dis"},{"key":"10338_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.4065\/82.4.441","volume":"82","author":"TH Oh","year":"2007","unstructured":"Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Basford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441\u20137.","journal-title":"Mayo Clin Proc"},{"key":"10338_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mus.26996","volume":"62","author":"JD Triplett","year":"2020","unstructured":"Triplett JD, Pinto MV, Hosfield EA, Milone M, Liewluck T. Myopathies featuring early or prominent dysphagia. Muscle Nerve. 2020;62:344\u201350.","journal-title":"Muscle Nerve"},{"key":"10338_CR13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993\u20132000.","journal-title":"N Engl J Med"},{"key":"10338_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/jnnp-2016-313418","volume":"87","author":"MC Dalakas","year":"2016","unstructured":"Dalakas MC. Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. J Neurol Neurosurg Psychiatry. 2016;87:1037.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrrheum.2018.54","volume":"14","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC. Are autoantibodies pathogenic in necrotizing myopathy? Nat Rev Rheumatol. 2018;14:251\u20132.","journal-title":"Nat Rev Rheumatol"},{"key":"10338_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMc1911058","volume":"381","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC. Case 22\u20132019: a 65-year-old woman with myopathy. N Engl J Med. 2019;381:1693.","journal-title":"N Engl J Med"},{"key":"10338_CR17","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1093\/brain\/awr217","volume":"134","author":"FM Cox","year":"2011","unstructured":"Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167\u201375.","journal-title":"Brain"},{"key":"10338_CR18","doi-asserted-by":"publisher","first-page":"116764","DOI":"10.1016\/j.jns.2020.116764","volume":"413","author":"K Taira","year":"2020","unstructured":"Taira K, Yamamoto T, Mori-Yoshimura M, Fujita S, Oya Y, Nishino I, et al. Obstruction-related dysphagia in inclusion body myositis: cricopharyngeal bar on videofluoroscopy indicates risk of aspiration. J Neurol Sci. 2020;413:116764.","journal-title":"J Neurol Sci"},{"key":"10338_CR19","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00415-009-5229-9","volume":"256","author":"FM Cox","year":"2009","unstructured":"Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol. 2009;256:2009\u201313.","journal-title":"J Neurol"},{"key":"10338_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/00005537-199807000-00009","volume":"108","author":"SM Houser","year":"1998","unstructured":"Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope. 1998;108:1001\u20135.","journal-title":"Laryngoscope"},{"key":"10338_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712\u20136.","journal-title":"Neurology"},{"key":"10338_CR22","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/jnnp.51.12.1542","volume":"51","author":"AR Wintzen","year":"1988","unstructured":"Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51:1542\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1212\/WNL.43.6.1241","volume":"43","author":"DS Riminton","year":"1993","unstructured":"Riminton DS, Chambers ST, Parkin PJ, Pollock M, Donaldson IM. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43:1241\u20131.","journal-title":"Neurology"},{"key":"10338_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/brain\/112.3.727","volume":"112","author":"BP Lotz","year":"1989","unstructured":"Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: observations in 40 patients. Brain. 1989;112:727\u201347.","journal-title":"Brain"},{"key":"10338_CR25","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/brain\/awp104","volume":"132","author":"MC Dalakas","year":"2009","unstructured":"Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132:1536\u201344.","journal-title":"Brain"},{"key":"10338_CR26","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1212\/NXI.0000000000000581","volume":"6","author":"ML Kosmidis","year":"2019","unstructured":"Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC. Trial of canakinumab, an IL-1\u03b2 receptor antagonist, in patients with inclusion body myositis. Neurol Neuroimmunol Neuroinflamm. 2019;6:e581.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10338_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","volume":"334","author":"ML Kosmidis","year":"2013","unstructured":"Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334:123\u20135.","journal-title":"J Neurol Sci"},{"key":"10338_CR28","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","volume":"73","author":"M Zong","year":"2014","unstructured":"Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014;73:913\u201320.","journal-title":"Ann Rheum Dis"},{"key":"10338_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29444","author":"RA McMillan","year":"2021","unstructured":"McMillan RA, Bowen AJ, Bayan SL, Kasperbauer JL, Ekbom DC. Cricopharyngeal myotomy in inclusion body myositis: comparison of endoscopic and transcervical approaches. Laryngoscope. 2021. https:\/\/doi.org\/10.1002\/lary.29444.","journal-title":"Laryngoscope"},{"key":"10338_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","volume":"87","author":"TH Oh","year":"2008","unstructured":"Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87:883\u20139.","journal-title":"Am J Phys Med Rehabil"},{"key":"10338_CR31","doi-asserted-by":"publisher","first-page":"CCRep.S10200","DOI":"10.4137\/CCRep.S10200","volume":"6","author":"K Murata","year":"2013","unstructured":"Murata K, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with dysphagia. Clin Med Insights Case Rep. 2013;6:CCRep.S10200.","journal-title":"Clin Med Insights Case Rep"},{"key":"10338_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2147\/IJGM.S198031","volume":"12","author":"N Mohannak","year":"2019","unstructured":"Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. IJGM. 2019;12:465\u201374.","journal-title":"IJGM"},{"key":"10338_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-020-00950-3","volume":"22","author":"R Zeng","year":"2020","unstructured":"Zeng R, Schmidt J. Impact and management of dysphagia in inflammatory myopathies. Curr Rheumatol Rep. 2020;22:74.","journal-title":"Curr Rheumatol Rep"},{"key":"10338_CR34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.55.2.296","volume":"55","author":"A Peng","year":"2000","unstructured":"Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology. 2000;55:296\u20138.","journal-title":"Neurology"},{"key":"10338_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","volume":"23","author":"JM Lindstrom","year":"2000","unstructured":"Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23:453\u201377.","journal-title":"Muscle Nerve"},{"key":"10338_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365\u20138.","journal-title":"Nat Med"},{"key":"10338_CR37","doi-asserted-by":"crossref","unstructured":"Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handbook of Clinical Neurology [Internet]. Elsevier; 2016 [cited 2020 Sep 21]. p. 447\u201366. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780444634320000244","DOI":"10.1016\/B978-0-444-63432-0.00024-4"},{"key":"10338_CR38","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978\u201380.","journal-title":"Neurology"},{"key":"10338_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1259\/0007-1285-35-409-43","volume":"35","author":"JP Murray","year":"1962","unstructured":"Murray JP. Deglutition in myasthenia gravis. BJR. 1962;35:43\u201352.","journal-title":"BJR"},{"key":"10338_CR40","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/jnnp.2004.038430","volume":"76","author":"M Llabres","year":"2005","unstructured":"Llabres M. Dysphagia as the sole manifestation of myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005;76:1297\u2013300.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0022-5223(19)35365-6","volume":"95","author":"MH Huang","year":"1988","unstructured":"Huang MH, King KL, Chien KY. Esophageal manometric studies in patients with myasthenia gravis. J Thorac Cardiovasc Surg. 1988;95:281\u20135.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10338_CR42","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","volume":"505","author":"D Grob","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci. 1987;505:472\u201399.","journal-title":"Ann NY Acad Sci"},{"key":"10338_CR43","doi-asserted-by":"crossref","unstructured":"Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology*. Incidence of myasthenia gravis in the Emilia-Romagna region: A prospective multicenter study. Neurology. 1998;51: 255\u20138.","DOI":"10.1212\/WNL.51.1.255"},{"key":"10338_CR44","doi-asserted-by":"publisher","first-page":"922???928","DOI":"10.1288\/00005537-197906000-00008","volume":"89","author":"RJ Carpenter","year":"1979","unstructured":"Carpenter RJ, Mcdonald TJ, Howard FM. The otolaryngologic presentation of myasthenia gravis. Laryngoscope. 1979;89:922???928.","journal-title":"Laryngoscope"},{"key":"10338_CR45","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.24875\/CIRUE.M18000011","volume":"86","author":"G Arellano-Aguilar","year":"2019","unstructured":"Arellano-Aguilar G, N\u00fa\u00f1ez-Mojica ES, Guti\u00e9rrez-Velazco JL, Dom\u00ednguez-Carrillo LG. Paraneoplastic Lambert-Eaton syndrome in a patient with disseminated metastatic cancer. CIRUE. 2019;86:1948.","journal-title":"CIRUE"},{"key":"10338_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15:113\u201324.","journal-title":"Nat Rev Neurol"},{"key":"10338_CR47","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1212\/WNL.48.Suppl_5.64S","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology. 1997;48:64S-9S.","journal-title":"Neurology"},{"key":"10338_CR48","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","volume":"16","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16:601\u201317.","journal-title":"Nat Rev Neurol"},{"key":"10338_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","volume":"13","author":"JD L\u00fcnemann","year":"2016","unstructured":"L\u00fcnemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13:34\u201346.","journal-title":"Neurotherapeutics"},{"key":"10338_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJM195607122550201","volume":"255","author":"M Fisher","year":"1956","unstructured":"Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255:57\u201365.","journal-title":"N Engl J Med"},{"key":"10338_CR51","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/archneur.64.10.1519","volume":"64","author":"T Nagashima","year":"2007","unstructured":"Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barr\u00e9 syndrome. Arch Neurol. 2007;64:1519\u201323.","journal-title":"Arch Neurol"},{"key":"10338_CR52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp-2013-305397","volume":"85","author":"BR Wakerley","year":"2014","unstructured":"Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85:339\u201344.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR53","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2169\/internalmedicine.3395-19","volume":"59","author":"M Arakawa","year":"2020","unstructured":"Arakawa M, Yamazaki M, Toda Y, Ozawa A, Kimura K. An oculopharyngeal subtype of Guillain-Barr\u00e9 syndrome sparing the trochlear and abducens nerves. Intern Med. 2020;59:1215\u20137.","journal-title":"Intern Med"},{"key":"10338_CR54","doi-asserted-by":"publisher","first-page":"e234316","DOI":"10.1136\/bcr-2020-234316","volume":"13","author":"K Patel","year":"2020","unstructured":"Patel K, Nussbaum E, Sico J, Merchant N. Atypical case of Miller-Fisher syndrome presenting with severe dysphagia and weight loss. BMJ Case Rep. 2020;13:e234316.","journal-title":"BMJ Case Rep"},{"key":"10338_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jns.2009.02.340","volume":"281","author":"B Edvardsson","year":"2009","unstructured":"Edvardsson B, Persson S. Polyneuritis cranialis presenting with anti-GQ1b IgG antibody. J Neurol Sci. 2009;281:125\u20136.","journal-title":"J Neurol Sci"},{"key":"10338_CR56","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0165-5728(97)00197-5","volume":"82","author":"AA Ilyas","year":"1998","unstructured":"Ilyas AA, Cook SD, Mithen FA, Taki T, Kasama T, Handa S, et al. Antibodies to GT1a ganglioside in patients with Guillain-Barr\u00e9 syndrome. J Neuroimmunol. 1998;82:160\u20137.","journal-title":"J Neuroimmunol"},{"key":"10338_CR57","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2018.1058","volume":"75","author":"E Dirlikov","year":"2018","unstructured":"Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Mu\u00f1oz-Jordan JL, et al. Clinical features of Guillain-Barr\u00e9 syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA Neurol. 2018;75:1089.","journal-title":"JAMA Neurol"},{"key":"10338_CR58","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1600-0404.2008.01107.x","volume":"119","author":"D Orlikowski","year":"2009","unstructured":"Orlikowski D, Terzi N, Blumen M, Sharshar T, Raphael JC, Annane D, et al. Tongue weakness is associated with respiratory failure in patients with severe Guillain-Barr\u00e9 syndrome. Acta Neurol Scand. 2009;119:364\u201370.","journal-title":"Acta Neurol Scand"},{"key":"10338_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF00385793","volume":"11","author":"MYM Chen","year":"1996","unstructured":"Chen MYM, Donofrio PD, Frederick MG, Ott DJ, Pikna LA. Videofluoroscopic evaluation of patients with Guillain-Barr\u00e9 syndrome. Dysphagia. 1996;11:11\u20133.","journal-title":"Dysphagia"},{"key":"10338_CR60","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/WNP.0000000000000380","volume":"34","author":"T Mengi","year":"2017","unstructured":"Mengi T, Se\u00e7il Y, \u0130ncesu TK, Arici \u015e, Akkiraz Z\u00d6, G\u00fcrg\u00f6r N, et al. Guillain-Barr\u00e9 syndrome and swallowing dysfunction. J Clin Neurophysiol. 2017;34:393\u20139.","journal-title":"J Clin Neurophysiol"},{"key":"10338_CR61","doi-asserted-by":"publisher","first-page":"e781","DOI":"10.1212\/NXI.0000000000000781","volume":"7","author":"MC Dalakas","year":"2020","unstructured":"Dalakas MC. Guillain-Barr\u00e9 syndrome: the first documented COVID-19\u2013triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020;7:e781.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10338_CR62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000009921","volume":"95","author":"F Costello","year":"2020","unstructured":"Costello F, Dalakas MC. Cranial neuropathies and COVID-19: Neurotropism and autoimmunity. Neurology. 2020;95:195\u20136.","journal-title":"Neurology"},{"key":"10338_CR63","doi-asserted-by":"publisher","unstructured":"Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2010 [cited 2020 Sep 27]. p. CD002063.pub4. Available from: http:\/\/doi.wiley.com\/https:\/\/doi.org\/10.1002\/14651858.CD002063.pub4","DOI":"10.1002\/14651858.CD002063.pub4"},{"key":"10338_CR64","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367\u201375.","journal-title":"JAMA"},{"key":"10338_CR65","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2169\/internalmedicine.54.4300","volume":"54","author":"H Teramoto","year":"2015","unstructured":"Teramoto H, Morita A, Hara M, Ninomiya S, Shigihara S, Kusunoki S, et al. Relapse with dysphagia in a case of chronic inflammatory demyelinating polyradiculoneuropathy. Intern Med. 2015;54:1791\u20133.","journal-title":"Intern Med"},{"key":"10338_CR66","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s10072-006-0664-1","volume":"27","author":"S Mazzucco","year":"2006","unstructured":"Mazzucco S, Ferrari S, Mezzina C, Tomelleri G, Bertolasi L, Rizzuto N. Hyperpyrexia-triggered relapses in an unusual case of ataxic chronic inflammatory demyelinating polyradiculoneuropathy. Neurol Sci. 2006;27:176\u20139.","journal-title":"Neurol Sci"},{"key":"10338_CR67","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1212\/NXI.0000000000000149","volume":"2","author":"L Querol","year":"2015","unstructured":"Querol L, Rojas-Garc\u00eda R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10338_CR68","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik IN, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35\u201346.","journal-title":"Lancet Neurol"},{"key":"10338_CR69","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/jnnp.2009.177576","volume":"81","author":"G Bedi","year":"2010","unstructured":"Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry. 2010;81:634\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR70","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1212\/WNL.35.8.1173","volume":"35","author":"PJ Dyck","year":"1985","unstructured":"Dyck PJ, O\u2019Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985;35:1173\u20136.","journal-title":"Neurology"},{"key":"10338_CR71","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/PPO.0b013e31826c5ad5","volume":"18","author":"JM Baehring","year":"2012","unstructured":"Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J. 2012;18:463\u20138.","journal-title":"Cancer J"},{"key":"10338_CR72","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.mayocp.2019.02.003","volume":"94","author":"A Zekeridou","year":"2019","unstructured":"Zekeridou A, Lennon VA. Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc. 2019;94:1865\u201378.","journal-title":"Mayo Clin Proc"},{"key":"10338_CR73","doi-asserted-by":"publisher","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you \u201ctake the brakes off\u201d the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.","journal-title":"Ther Adv Neurol Disord"},{"key":"10338_CR74","first-page":"1359","volume":"20","author":"S Muppidi","year":"2014","unstructured":"Muppidi S, Vernino S. Paraneoplastic neuropathies. Continuum (Minneap Minn). 2014;20:1359\u201372.","journal-title":"Continuum (Minneap Minn)"},{"key":"10338_CR75","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/WCO.0b013e328364c020","volume":"26","author":"F Graus","year":"2013","unstructured":"Graus F, Dalmau J. Paraneoplastic neuropathies. Curr Opin Neurol. 2013;26:489\u201395.","journal-title":"Curr Opin Neurol"},{"key":"10338_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/jnnp.67.1.7","volume":"67","author":"JC Antoine","year":"1999","unstructured":"Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry. 1999;67:7\u201314.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR77","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/jnnp.2007.125930","volume":"79","author":"K Viala","year":"2008","unstructured":"Viala K, B\u00e9hin A, Maisonobe T, L\u00e9ger J-M, Stojkovic T, Davi F, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry. 2008;79:778\u201382.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR78","doi-asserted-by":"publisher","first-page":"e2291","DOI":"10.1097\/MD.0000000000002291","volume":"94","author":"J Ni","year":"2015","unstructured":"Ni J, Weng L, Liu M, Yang H, Wang Y. Small cell lung cancer accompanied by tonsillar metastasis and anti-hu antibody-associated paraneoplastic neuropathy: a rare case report with long-term survival. Medicine. 2015;94:e2291.","journal-title":"Medicine"},{"key":"10338_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2868190","volume":"2016","author":"JC Yeung","year":"2016","unstructured":"Yeung JC, Pringle CE, Sekhon HS, Kilty SJ, Macdonald K. Bilateral vocal cord paralysis and cervicolumbar radiculopathy as the presenting paraneoplastic manifestations of small cell lung cancer: a case report and literature review. Case Rep Otolaryngol. 2016;2016:1\u20135.","journal-title":"Case Rep Otolaryngol"},{"key":"10338_CR80","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.10518","volume":"53","author":"SJ Pittock","year":"2003","unstructured":"Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53:580\u20137.","journal-title":"Ann Neurol"},{"key":"10338_CR81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/NRL.0b013e3181c92a72","volume":"16","author":"V Terushkin","year":"2010","unstructured":"Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al. Neurosarcoidosis: presentations and management. Neurologist. 2010;16:2\u201315.","journal-title":"Neurologist"},{"key":"10338_CR82","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.14309\/ajg.0000000000000171","volume":"114","author":"P Brito-Zer\u00f3n","year":"2019","unstructured":"Brito-Zer\u00f3n P, Bari K, Baughman RP, Ramos-Casals M. Sarcoidosis involving the gastrointestinal tract: diagnostic and therapeutic management. Am J Gastroenterol. 2019;114:1238\u201347.","journal-title":"Am J Gastroenterol"},{"key":"10338_CR83","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00296-011-2242-y","volume":"33","author":"K Nishikubo","year":"2013","unstructured":"Nishikubo K, Hyodo M, Kawakami M, Kobayashi T. A rare manifestation of cricopharyngeal myopathy presenting with dysphagia in sarcoidosis. Rheumatol Int. 2013;33:1089\u201392.","journal-title":"Rheumatol Int"},{"key":"10338_CR84","doi-asserted-by":"publisher","first-page":"175628641880573","DOI":"10.1177\/1756286418805732","volume":"11","author":"S Zella","year":"2018","unstructured":"Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Th\u00f6ne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732.","journal-title":"Ther Adv Neurol Disord"},{"key":"10338_CR85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaut.2012.01.003","volume":"39","author":"PP Pavlakis","year":"2012","unstructured":"Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, et al. Peripheral neuropathies in Sj\u00f6gren\u2019s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012;39:27\u201333.","journal-title":"J Autoimmun"},{"key":"10338_CR86","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/jnnp.2010.222109","volume":"82","author":"PP Pavlakis","year":"2011","unstructured":"Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011;82:798\u2013802.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR87","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.semarthrit.2011.04.001","volume":"41","author":"B Florica","year":"2011","unstructured":"Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2011;41:203\u201311.","journal-title":"Semin Arthritis Rheum"},{"key":"10338_CR88","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/bmj.2.6183.173","volume":"2","author":"ME Edmonds","year":"1979","unstructured":"Edmonds ME, Jones TC, Saunders WA, Sturrock RD. Autonomic neuropathy in rheumatoid arthritis. Br Med J. 1979;2:173\u20135.","journal-title":"Br Med J"},{"key":"10338_CR89","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/mus.20716","volume":"35","author":"F Poglio","year":"2007","unstructured":"Poglio F, Mongini T, Cocito D. Sensory ataxic neuropathy and esophageal achalasia in a patient with Sjogren\u2019s syndrome. Muscle Nerve. 2007;35:532\u20135.","journal-title":"Muscle Nerve"},{"key":"10338_CR90","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3389\/fneur.2020.00787","volume":"11","author":"JMS Sanchez","year":"2020","unstructured":"Sanchez JMS, McNally JS, Cortez MM, Hemp J, Pace LA, Clardy SL. Neuroimmunogastroenterology: at the interface of neuroimmunology and gastroenterology. Front Neurol. 2020;11:787.","journal-title":"Front Neurol"},{"key":"10338_CR91","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.cgh.2008.04.009","volume":"6","author":"R Dhamija","year":"2008","unstructured":"Dhamija R, Tan KM, Pittock SJ, Foxx-Orenstein A, Benarroch E, Lennon VA. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol. 2008;6:988\u201392.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10338_CR92","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00535-018-1477-8","volume":"53","author":"A Mukaino","year":"2018","unstructured":"Mukaino A, Minami H, Isomoto H, Hamamoto H, Ihara E, Maeda Y, et al. Anti-ganglionic AChR antibodies in Japanese patients with motility disorders. J Gastroenterol. 2018;53:1227\u201340.","journal-title":"J Gastroenterol"},{"key":"10338_CR93","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/17474124.2019.1544890","volume":"13","author":"E D\u2019Amico","year":"2019","unstructured":"D\u2019Amico E, Zangh\u00ec A, Serra A, Murabito P, Zappia M, Patti F, et al. Management of dysphagia in multiple sclerosis: current best practice. Expert Rev Gastroenterol Hepatol. 2019;13:47\u201354.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10338_CR94","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s10072-008-1044-9","volume":"29","author":"C Tassorelli","year":"2008","unstructured":"Tassorelli C, Bergamaschi R, Buscone S, Bartolo M, Furnari A, Crivelli P, et al. Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurol Sci. 2008;29:360\u20133.","journal-title":"Neurol Sci"},{"key":"10338_CR95","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/1352458506073481","volume":"13","author":"MP Pender","year":"2007","unstructured":"Pender MP, Ferguson SM. Dysarthria and dysphagia due to the opercular syndrome in multiple sclerosis. Mult Scler. 2007;13:817\u20139.","journal-title":"Mult Scler"},{"key":"10338_CR96","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10072-015-2067-7","volume":"36","author":"X-L Guan","year":"2015","unstructured":"Guan X-L, Wang H, Huang H-S, Meng L. Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2015;36:671\u201381.","journal-title":"Neurol Sci"},{"key":"10338_CR97","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0022-510X(81)90083-6","volume":"49","author":"H Shibasaki","year":"1981","unstructured":"Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci. 1981;49:253\u201371.","journal-title":"J Neurol Sci"},{"key":"10338_CR98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000266286","volume":"46","author":"L Hartelius","year":"1994","unstructured":"Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson\u2019s disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46:9\u201317.","journal-title":"Folia Phoniatr Logop"},{"key":"10338_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/319201","volume":"2013","author":"DJ Levinthal","year":"2013","unstructured":"Levinthal DJ, Rahman A, Nusrat S, O\u2019Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:1\u20139.","journal-title":"Mult Scler Int"},{"key":"10338_CR100","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jns.2013.05.020","volume":"331","author":"C Solaro","year":"2013","unstructured":"Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, et al. Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire). J Neurol Sci. 2013;331:94\u20137.","journal-title":"J Neurol Sci"},{"key":"10338_CR101","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.joms.2012.05.008","volume":"71","author":"SA Danesh-Sani","year":"2013","unstructured":"Danesh-Sani SA, Rahimdoost A, Soltani M, Ghiyasi M, Haghdoost N, Sabzali-Zanjankhah S. Clinical assessment of orofacial manifestations in 500 patients with multiple sclerosis. J Oral Maxillofac Surg. 2013;71:290\u20134.","journal-title":"J Oral Maxillofac Surg"},{"key":"10338_CR102","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/154596839701100102","volume":"11","author":"S Abraham","year":"1997","unstructured":"Abraham S, Scheinberg LC, Smith CR, LaRocca NG. Neurologic impairment and disability status in outpatients with multiple sclerosis reporting dysphagia symptomatology. Neurorehabil Neural Repair. 1997;11:7\u201313.","journal-title":"Neurorehabil Neural Repair"},{"key":"10338_CR103","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0303-8467(02)00053-7","volume":"104","author":"A De Pauw","year":"2002","unstructured":"De Pauw A, Dejaeger E, D\u2019hooghe B, Carton H. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg. 2002;104:345\u201351.","journal-title":"Clin Neurol Neurosurg"},{"key":"10338_CR104","doi-asserted-by":"publisher","first-page":"460","DOI":"10.5935\/1808-8694.20130082","volume":"79","author":"AMF Fernandes","year":"2013","unstructured":"Fernandes AMF, de Campos DA, Eckley CA, da Silva L, Ferreira RB, Tilbery CP. Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity? Braz J Otorhinolaryngol. 2013;79:460\u20135.","journal-title":"Braz J Otorhinolaryngol"},{"key":"10338_CR105","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.clinph.2013.03.003","volume":"124","author":"E Alfonsi","year":"2013","unstructured":"Alfonsi E, Bergamaschi R, Cosentino G, Ponzio M, Montomoli C, Restivo DA, et al. Electrophysiological patterns of oropharyngeal swallowing in multiple sclerosis. Clin Neurophysiol. 2013;124:1638\u201345.","journal-title":"Clin Neurophysiol"},{"key":"10338_CR106","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s003300101086","volume":"12","author":"W Wiesner","year":"2002","unstructured":"Wiesner W, Wetzel SG, Kappos L, Hoshi MM, Witte U, Radue EW, et al. Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms. Eur Radiol. 2002;12:789\u201392.","journal-title":"Eur Radiol"},{"key":"10338_CR107","first-page":"707","volume":"39","author":"R Terr\u00e9-Boliart","year":"2004","unstructured":"Terr\u00e9-Boliart R, Orient-L\u00f3pez F, Guevara-Espinosa D, Ram\u00f3n-Rona S, Bernabeu-Guitart M. Clav\u00e9-Civit P [Oropharyngeal dysphagia in patients with multiple sclerosis]. Rev Neurol. 2004;39:707\u201310.","journal-title":"Rev Neurol"},{"key":"10338_CR108","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","volume":"31","author":"J Oh","year":"2018","unstructured":"Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31:752\u20139.","journal-title":"Curr Opin Neurol"},{"key":"10338_CR109","doi-asserted-by":"publisher","first-page":"e636","DOI":"10.1212\/NXI.0000000000000636","volume":"7","author":"JM Stankiewicz","year":"2020","unstructured":"Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e636.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10338_CR110","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307\u201316.","journal-title":"Lancet Neurol"},{"key":"10338_CR111","doi-asserted-by":"publisher","first-page":"s338","DOI":"10.1007\/s10072-006-0655-2","volume":"27","author":"DA Restivo","year":"2006","unstructured":"Restivo DA, Marchese-Ragona R, Patti F. Management of swallowing disorders in multiple sclerosis. Neurol Sci. 2006;27:s338-40.","journal-title":"Neurol Sci"},{"key":"10338_CR112","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473\u20137.","journal-title":"J Exp Med"},{"key":"10338_CR113","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","volume":"13","author":"KC O\u2019Connor","year":"2007","unstructured":"O\u2019Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13:211\u20137.","journal-title":"Nat Med"},{"key":"10338_CR114","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1001\/archneurol.2011.249","volume":"68","author":"KH Chan","year":"2011","unstructured":"Chan KH. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011;68:1432.","journal-title":"Arch Neurol"},{"key":"10338_CR115","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5692\/clinicalneurol.55.41","volume":"55","author":"A Koda","year":"2015","unstructured":"Koda A, Kaneko S, Asayama S, Fujita K, Kusaka H. Successful treatment of neuromyelitis optica spectrum disorder by early initiation of plasma exchange. Rinsho Shinkeigaku. 2015;55:41\u20134.","journal-title":"Rinsho Shinkeigaku"},{"key":"10338_CR116","doi-asserted-by":"publisher","first-page":"bcr-2018","DOI":"10.1136\/bcr-2018-227041","volume":"12","author":"O Cousins","year":"2019","unstructured":"Cousins O, Girelli E, Harikrishnan S. Neuromyelitis optica: an elusive cause of dysphagia. BMJ Case Rep. 2019;12:bcr-2018-227041.","journal-title":"BMJ Case Rep"},{"key":"10338_CR117","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/jnnp.2008.145391","volume":"79","author":"T Takahashi","year":"2008","unstructured":"Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008;79:1075\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10338_CR118","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"10338_CR119","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00401-018-1950-8","volume":"137","author":"S Hillebrand","year":"2019","unstructured":"Hillebrand S, Schanda K, Nigritinou M, Tsymala I, B\u00f6hm D, Peschl P, et al. Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathol. 2019;137:467\u201385.","journal-title":"Acta Neuropathol"},{"key":"10338_CR120","doi-asserted-by":"publisher","first-page":"e27412","DOI":"10.1371\/journal.pone.0027412","volume":"6","author":"J Ratelade","year":"2011","unstructured":"Ratelade J, Bennett JL, Verkman AS. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS ONE. 2011;6:e27412.","journal-title":"PLoS ONE"},{"key":"10338_CR121","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s00415-014-7298-7","volume":"261","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhang L, Zhang B, Dai Y, Kang Z, Lu C, et al. Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol. 2014;261:954\u201362.","journal-title":"J Neurol"},{"key":"10338_CR122","doi-asserted-by":"publisher","unstructured":"Pawlitzki M, Ahring S, Rolfes L, Dziewas R, Warnecke T, Suntrup\u2010Krueger S, et al. Dysphagia in NMOSD and MOGAD as a surrogate of brain involvement? Eur J Neurol. 2020;ene.14691. https:\/\/doi.org\/10.1111\/ene.14691.","DOI":"10.1111\/ene.14691"},{"key":"10338_CR123","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1056\/NEJM199104253241703","volume":"324","author":"BC Sonies","year":"1991","unstructured":"Sonies BC, Dalakas MC. Dysphagia in patients with the post-polio syndrome. N Engl J Med. 1991;324:1162\u20137.","journal-title":"N Engl J Med"},{"key":"10338_CR124","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","volume":"71","author":"S-Y Huh","year":"2014","unstructured":"Huh S-Y, Kim S-H, Hyun J-W, Joung A-R, Park MS, Kim B-J, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372.","journal-title":"JAMA Neurol"},{"key":"10338_CR125","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"S-H Kim","year":"2015","unstructured":"Kim S-H, Jeong IH, Hyun J-W, Joung A, Jo H-J, Hwang S-H, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72:989.","journal-title":"JAMA Neurol"},{"key":"10338_CR126","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394:1352\u201363.","journal-title":"Lancet"},{"key":"10338_CR127","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614\u201325.","journal-title":"N Engl J Med"},{"key":"10338_CR128","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","volume":"2","author":"K Chalmoukou","year":"2015","unstructured":"Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e131.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10338_CR129","doi-asserted-by":"publisher","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","volume":"44","author":"DH Whittam","year":"2020","unstructured":"Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251.","journal-title":"Mult Scler Relat Disord."},{"key":"10338_CR130","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280.","journal-title":"J Neuroinflamm"},{"key":"10338_CR131","doi-asserted-by":"publisher","first-page":"175628642110034","DOI":"10.1177\/17562864211003486","volume":"14","author":"P Tsiortou","year":"2021","unstructured":"Tsiortou P, Alexopoulos H, Dalakas MC. GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord. 2021;14:17562864211003486.","journal-title":"Ther Adv Neurol Disord"},{"key":"10338_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-018-1232-z","volume":"19","author":"G Rakocevic","year":"2019","unstructured":"Rakocevic G, Alexopoulos H, Dalakas MC. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurol. 2019;19:1.","journal-title":"BMC Neurol"},{"key":"10338_CR133","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1212\/01.wnl.0000237558.83349.d0","volume":"67","author":"G Rakocevic","year":"2006","unstructured":"Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006;67:1068\u201370.","journal-title":"Neurology"},{"key":"10338_CR134","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/brain\/awu142","volume":"137","author":"A Carvajal-Gonz\u00e1lez","year":"2014","unstructured":"Carvajal-Gonz\u00e1lez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137:2178\u201392.","journal-title":"Brain"},{"key":"10338_CR135","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1212\/01.wnl.0000436617.40779.65","volume":"81","author":"H Alexopoulos","year":"2013","unstructured":"Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology. 2013;81:1962\u20134.","journal-title":"Neurology"},{"key":"10338_CR136","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870\u20136.","journal-title":"N Engl J Med"},{"key":"10338_CR137","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ana.25002","volume":"82","author":"MC Dalakas","year":"2017","unstructured":"Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol. 2017;82:271\u20137.","journal-title":"Ann Neurol"},{"key":"10338_CR138","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/08830738050200021401","volume":"20","author":"R RamachandranNair","year":"2005","unstructured":"RamachandranNair R, Manoj P, Rafeequ M, Girija AS. Childhood acute disseminated encephalomyelitis presenting as Foix-Chavany-Marie syndrome. J Child Neurol. 2005;20:163\u20135.","journal-title":"J Child Neurol"},{"key":"10338_CR139","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/PEC.0b013e3181b0a443","volume":"25","author":"A Pittard","year":"2009","unstructured":"Pittard A, Abramo TJ, Arnold DH. A child with difficulty swallowing. Pediatr Emerg Care. 2009;25:525\u20138.","journal-title":"Pediatr Emerg Care"},{"key":"10338_CR140","doi-asserted-by":"publisher","first-page":"e5377","DOI":"10.1097\/MD.0000000000005377","volume":"95","author":"Y Ma","year":"2016","unstructured":"Ma Y, Sun X, Li W, Li Y, Kang T, Yang X, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with intracranial Epstein-Barr virus infection: a case report. Medicine. 2016;95:e5377.","journal-title":"Medicine."},{"key":"10338_CR141","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jneuroim.2013.04.004","volume":"259","author":"S Mundiyanapurath","year":"2013","unstructured":"Mundiyanapurath S, Jarius S, Probst C, St\u00f6cker W, Wildemann B, B\u00f6sel J. GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol. 2013;259:88\u201391.","journal-title":"J Neuroimmunol"},{"key":"10338_CR142","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1212\/WNL.0000000000000991","volume":"83","author":"WO Tobin","year":"2014","unstructured":"Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797\u2013803.","journal-title":"Neurology"},{"key":"10338_CR143","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00381-018-3720-2","volume":"34","author":"G Oz Tuncer","year":"2018","unstructured":"Oz Tuncer G, Teber S, Kutluk MG, Albayrak P, Deda G. Hashimoto\u2019s encephalopathy presenting as pseudobulbar palsy. Childs Nerv Syst. 2018;34:1251\u20134.","journal-title":"Childs Nerv Syst"},{"key":"10338_CR144","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1093\/brain\/awg233","volume":"126","author":"M Odaka","year":"2003","unstructured":"Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al. Bickerstaff\u2019s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barr\u00e9 syndrome. Brain. 2003;126:2279\u201390.","journal-title":"Brain"},{"key":"10338_CR145","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejpn.2018.11.008","volume":"23","author":"A Michev","year":"2019","unstructured":"Michev A, Musso P, Foiadelli T, Trabatti C, Lozza A, Franciotta D, et al. Bickerstaff brainstem encephalitis and overlapping Guillain-Barr\u00e9 syndrome in children: report of two cases and review of the literature. Eur J Paediatr Neurol. 2019;23:43\u201352.","journal-title":"Eur J Paediatr Neurol"},{"key":"10338_CR146","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","volume":"88","author":"C Gaig","year":"2017","unstructured":"Gaig C, Graus F, Compta Y, H\u00f6gl B, Bataller L, Br\u00fcggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736\u201343.","journal-title":"Neurology"},{"key":"10338_CR147","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","volume":"4","author":"JA Honorat","year":"2017","unstructured":"Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4:e385.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10338_CR148","doi-asserted-by":"publisher","first-page":"175628642090997","DOI":"10.1177\/1756286420909973","volume":"13","author":"X-L Li","year":"2020","unstructured":"Li X-L, Han J, Zhao H-T, Long Y-M, Zhang B-W, Wang H-Y. Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord. Ther Adv Neurol Disord. 2020;13:175628642090997.","journal-title":"Ther Adv Neurol Disord"},{"key":"10338_CR149","doi-asserted-by":"publisher","first-page":"e612","DOI":"10.1212\/NXI.0000000000000612","volume":"6","author":"S Shelly","year":"2019","unstructured":"Shelly S, Kryzer TJ, Komorowski L, Miske R, Anderson MD, Flanagan EP, et al. Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2019;6:e612.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10338_CR150","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jneuroim.2017.05.011","volume":"309","author":"U Wallwitz","year":"2017","unstructured":"Wallwitz U, Brock S, Schunck A, Wildemann B, Jarius S, Hoffmann F. From dizziness to severe ataxia and dysarthria: New cases of anti-Ca\/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum. J Neuroimmunol. 2017;309:77\u201381.","journal-title":"J Neuroimmunol"},{"key":"10338_CR151","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/ncpneuro0287","volume":"2","author":"J Castle","year":"2006","unstructured":"Castle J, Sakonju A, Dalmau J, Newman-Toker DE. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple\u2019s disease. Nat Rev Neurol. 2006;2:566\u201372.","journal-title":"Nat Rev Neurol"}],"container-title":["Dysphagia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00455-021-10338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00455-021-10338-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00455-021-10338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T17:07:05Z","timestamp":1675530425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00455-021-10338-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":151,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10338"],"URL":"https:\/\/doi.org\/10.1007\/s00455-021-10338-9","relation":{},"ISSN":["0179-051X","1432-0460"],"issn-type":[{"value":"0179-051X","type":"print"},{"value":"1432-0460","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This material is the authors' own original work, which has not been previously published or considered for publication elsewhere. The paper properly credits the meaningful contributions of co-authors and co-researchers. All sources used are properly disclosed. All authors have been personally and actively involved in substantial work leading to the paper and will take public responsibility for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}